BioPharma Credit PLC

Company Profile

BioPharma Credit PLC had its IPO on under the ticker symbol BOPCF.

The company operates in the sector and industry. BioPharma Credit PLC has a staff strength of 0 employees.

Stock update

Shares of BioPharma Credit PLC opened at $0.83 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.83 - $0.83, and closed at $0.83.

This is a -4.62% slip from the previous day's closing price.

A total volume of 13,186 shares were traded at the close of the day’s session.

In the last one week, shares of BioPharma Credit PLC have slipped by -4.62%.

BioPharma Credit PLC's Key Ratios

BioPharma Credit PLC has a market cap of $1.27 billion, indicating a price to book ratio of 0 and a price to sales ratio of 10.6251.

In the last 12-months BioPharma Credit PLC’s revenue was $218.17 million with a gross profit of $103.88 million and an EBITDA of $0. The EBITDA ratio measures BioPharma Credit PLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, BioPharma Credit PLC’s operating margin was 83.58% while its return on assets stood at 8.34% with a return of equity of 13.5%.

In Q2, BioPharma Credit PLC’s quarterly earnings growth was a positive 184.5% while revenue growth was a positive 174.1%.

BioPharma Credit PLC’s PE and PEG Ratio

Forward PE

0

Trailing PE

14.6774

PEG

Its diluted EPS in the last 12-months stands at $0.062 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BioPharma Credit PLC’s profitability.

BioPharma Credit PLC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 10.6251.

BioPharma Credit PLC stock pays annual dividends of $0.07 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0

Total Liabilities

$4.00 million

Operating Cash Flow

$-29453500.00

Capital Expenditure

$0

Dividend Payout Ratio

0%

BioPharma Credit PLC ended 2024 with $0 in total assets and $0 in total liabilities. Its intangible assets were valued at $0 while shareholder equity stood at $0.

BioPharma Credit PLC ended 2024 with $0 in deferred long-term liabilities, $4.00 million in other current liabilities, 13739000.00 in common stock, $762.93 million in retained earnings and $0 in goodwill. Its cash balance stood at $0 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

BioPharma Credit PLC’s total current assets stands at $56.32 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $45.88 million compared to accounts payable of $0 and inventory worth $0.

In 2024, BioPharma Credit PLC's operating cash flow was $-29453500.00 while its capital expenditure stood at $0.

Comparatively, BioPharma Credit PLC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.83

52-Week High

$1

52-Week Low

$0.9

Analyst Target Price

$

BioPharma Credit PLC stock is currently trading at $0.83 per share. It touched a 52-week high of $1 and a 52-week low of $1. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.9 and 200-day moving average was $0 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 769.4% of the company’s stock are held by insiders while 3921.6% are held by institutions.